PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-08-26 Novosom Smarticles® to Encapsulate Isis Antisense Drugs Novosom has licensed antisense drugs from Isis to which it will apply its Smarticle® technology for effective delivery. This agreement is yet another opportunity for Novosom to validate the potential of its proprietary technology.
- Published on: 2008-08-26 QLT Continues to Divest its Portfolio As part of its restructuring programme announced on the back of falling revenues of its leading product, Visudyne® (verteporfin), QLT has divested another core asset by licensing out its Atrigel® drug delivery technology to Reckitt Benckiser for US$25 M.
- Published on: 2008-08-19 Bristol-Myers Squibb Deal Provides PDL with Much Needed Boost PDL BioPharma, a biotech that’s recently been forced to sell a number of its key assets, has announced some positive news in the form of a deal with Bristol-Myers Squibb for PDL’s Phase I multiple myeloma candidate, elotuzumab. PDL will receive US$30 M upfront and potential milestones that could total US$680 M if the product is successfully developed and marketed.
- Published on: 2008-08-19 Cel-Sci’s Multikine Could be Distributed by Teva in Turkey and Israel Cel-Sci has granted Teva exclusive marketing and distribution rights for its lead candidate, Multikine, within Turkey and Israel. With its unique mode of action, Multikine has the potential to reach blockbuster status though the drug must still successfully complete Phase III trials.
- Published on: 2008-08-15 Cytos Signs Vaccines Deal with Pfizer Cytos Biotechnology has entered into an exclusive agreement with Pfizer to research, develop, manufacture and commercialise novel vaccines for a defined number of human diseases. For Cytos, the deal could be worth up to US$137 M.
- Published on: 2008-08-12 CSL Seeks to Solidfy its Position by Acquiring Talecris CSL has agreed to buy Talecris Biotherapeutics for US$3.1 B and will be hoping that the acquisition will be passed by the competition regulators. If it goes through, CSL will strengthen its position in the global plasma market just behind the leader, Baxter International.
- Published on: 2008-08-08 Archemix in Yet Another Deal for its Aptamer Technology Archemix’s expertise and extensive IP portfolio, associated with the discovery and development of aptamers, has resulted in its latest agreement with the Japanese company, Ribomic. The license to access certain rights from Archemix’s IP portfolio is non-exclusive, but Ribomic has the option to convert it to an exclusive license for a particular target subject to a fee.
- Published on: 2008-08-06 The Medicines Company Acquires Curacyte and its Lead Antithrombotic Curacyte AG sold its subsidiary, Curacyte Discovery and its lead compound to The Medicines Company. CU-2010 is in preclinical development for surgical blood loss and could address an urgent medical need following the withdrawal of Bayer's antifibronolytic, aprotinin.
- Published on: 2008-08-06 Eli Lilly’s Novel Financing Approach to R&D Eli Lilly has entered into a number of interesting agreements to reduce costs and increase productivity – one of which is with Covance. The pharmaceutical industry is increasingly outsourcing key functions to reduce costs and speed up drug development times and companies like Aventis and Amgen have both made similar moves with Quintiles in the past.
- Published on: 2008-08-04 Valeant Pharmaceuticals’ De-Globalisation Strategy Sees the Sale of European Operations Valeant Pharmaceuticals sold its Western and Eastern European pharmaceutical business to Meda, giving Meda an opportunity to enter the Russian market. For Valeant, this is one of many agreements signed to achieve its goal of reducing its worldwide operations.
Review and Analysis, Navigation
Bookmarks
Bookmark PharmaDeals through one of these social networks.
